Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches Fourth Human Study for Reducing Hypertension, Reports Positive Outcome of Third Human Study’s Data

Global drug delivery innovator Lexaria Bioscience is researching the ability of its patented DehydraTECH(TM) technology to improve the performance of a number of prescription drugs
Lexaria is a world leader in the investigation of a DehydraTECH-processed cannabidiol (“CBD”) to potentially treat high blood pressure (hypertension), and study outcomes thus far have rendered positive results on effectiveness and patient tolerance
The company is building a scorecard of data to support its planned FDA application for formal, registered clinical testing under the Investigational New Drug (“IND”) process
Lexaria recently completed all data analyses of its HYPER-H21-3 study examining DehydraTECH-CBD’s ability to reduce pulmonary artery systolic pressure, and launched HYPER-H21-4 to gather a variety of data points related to DehydraTECH-CBD’s use over a more extensive period of time

High blood pressure has long been labeled “the silent killer” because of its propensity to lead to incapacitating or prematurely deadly strokes, heart attacks and other serious disease indications without necessarily foreshadowing pain or great discomfort. According to the World Health Organization (“WHO”), an estimated 1.28 billion adults aged 30-79 years worldwide have hypertension but only about 1 in 5 (21 percent) people with the condition have it under control with medical treatment (https://cnw.fm/jDeE3).

During the past decade within the United States, about 49 percent of the population reported taking at least one prescription medication in the past 30 days in data sampling collected by the National Center for Health Statistics of the Centers for Disease Control and Prevention at selected times, while 24 percent of the individuals took three or more prescriptions and 13 percent took five or more (https://cnw.fm/dQJac).

The data showed a marked increase over those persons sampled during the late 1980s to mid-1990s, particularly where multiple medications were concerned. And yet, a recent news report states that as few as 50 percent of patients take their medications exactly as prescribed (https://cnw.fm/pjMQN).

Global drug delivery innovator Lexaria Bioscience (NASDAQ: LEXX) is devoting its research and product development to making drug substances more effective in their approach to treating medical conditions such as high blood pressure and, in the process, to overcoming many of the obstacles that may hinder their proper use by patients.

The company’s patented DehydraTECH(TM) technology combines an active pharmaceutical ingredient (“API”) with a fatty acid oil and performing a patented dehydration synthesis process before ingestion The Company has demonstrated significant improvements of absorption into bloodstream and even into brain tissue, in as little as minutes after ingestion.

One area of Lexaria’s research has focused on pursuing U.S. Food and Drug Administration (“FDA”) approval to begin formal, registered clinical testing of its DehydraTECH-processed cannabidiol (“CBD”) for the treatment of hypertension under the Investigational New Drug (“IND”) process.

Lexaria recently announced the launch of its HYPER-H21-4 randomized, double blinded, placebo-controlled, cross-over study of DehydraTECH-CBD in relation to hypertension, with the potential for enhancing Lexaria’s ability to treat cardiovascular and other disease states beyond hypertension that are related to increased arterial stiffness (https://cnw.fm/Wg5qZ).

Lexaria has already completed other human studies. Last year, studies HYPER-H21-1 (https://cnw.fm/qGvMi) and HYPER-H21-2 (https://cnw.fm/Na1s4) provided evidence that DehydraTECH-CBD successfully reduced blood pressure in similarly hypertensive human volunteers, and Lexaria announced earlier this month that it had completed all data analyses of its HYPER-H21-3 study with positive safety and efficacy findings (https://cnw.fm/nFuNt).

HYPER-H21-3 used a placebo-controlled and double-blinded design with 16 volunteers, safely simulating hypoxia conditions (reduced oxygen availability) to induce lung artery constriction, or pulmonary hypertension, to analyze the ability of DehydraTECH-CBD to reduce pulmonary artery systolic pressure.

HYPER-H21-4 will include 60 people and will be the most comprehensive study Lexaria has conducted to date. Dosing in more than half the volunteers has already begun and all treatment visits are expected to be finished by early July.

The volunteers are between the ages of 40 and 70 with documented or measured elevated blood pressure, mild hypertension or moderate (stage 2) hypertension. The participants will use an escalating dose of DehydraTECH-CBD every day for a 5-week duration, establishing data for DehydraTECH-CBD’s extended use over time and providing secondary data outcomes that may ultimately lead to additional applications for DehydraTECH-CBD, according to the company.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text “CCWIRE” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

CanadianCannabisWire is part of the InvestorBrandNetwork.

420 with CNW — New Poll Suggests Parents Are Willing to Give Kids CBD

Cannabidiol (CBD) is a chemical compound produced by plants in the cannabis family. Since most of the CBD on the American market is extracted from hemp, a nonpsychoactive form of cannabis, cannabidiol will not intoxicate you. For the past couple of years, people have been turning to this hemp extract as an alternative medicine for a variety of health problems. Studies have shown that it can be effective at alleviating the symptoms of medical conditions such as chronic pain, anxiety depression and insomnia.

Furthermore, the FDA has approved a CBD-based drug called Epidiolex to treat two rare forms of pediatric epilepsy: Dravet syndrome and Lennox-Gastaut syndrome.

Experts have cautioned the public against seeing CBD as a miracle cure that can treat any condition, stating the hype around CBD treatments seems to have eclipsed the science. There is limited research on cannabidiol, and we still don’t know much about its potential benefits and risks, especially over the long term.

This problem becomes even more serious when you consider the fact that there are companies making CBD products for children with barely any regulation from the federal government. And according to a new report from the University of Michigan’s C.S. Mott Children’s Hospital, some parents are willing to give their children CBD.

Researchers surveyed 2,020 parents with at least one child aged one to eighteen years old. They discovered that three in four parents were receptive to the idea of giving their children CBD if other medications were not effective. Sarah Clark, the poll’s codirector, says the results point to parents being more open-minded about CBD treatments.

However, the report noted that most parents do not have access to crucial information about CBD. One-third of the respondents didn’t know that CBD was nonpsychoactive and believed that using the cannabinoid is no different from using marijuana. Such parents would be more likely to prevent their children from using CBD even when they could benefit

Clark believes that parents who don’t understand the difference between CBD and THC (the main psychoactive agent in cannabis) can be properly educated via continued exposure and explanation. On the other hand, she is optimistic that the respondents who expressed that they would give their children CBD if other medications did not work at least have a basic understanding of the cannabinoid. Those parents realize that there is no miracle medicine that can cure every childhood ailment, she says.

The poll also revealed that 83% of parents believed the FDA should regulate CBD products meant for children, and 74% feel that you should have a doctor’s prescription before you can give CBD to your children.

With such a willingness to give CBD to kids, parents could soon take to the cutting-edge cannabis cultivation “micro-farms” made and marketed by entities such as Advanced Container Technologies Inc. (OTC: ACTX) as these companies seek to take matters into their own hands while federal regulators consider ways to regulate this nonintoxicating cannabinoid.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — A Look at the Relationship Between Different Social Media Platforms and Marijuana

The cannabis industry operates in a sort of regulatory limbo where dozens of states have legal cannabis markets, but federal law explicitly outlaws the production and sale of cannabis. This means that although marijuana businesses pay taxes, there are significant restrictions placed on them by federal legislations.

One restriction placed on the cannabis industry is on advertising. For example, because the controversial plant is considered a Class I controlled substance with a high potential for abuse, the Cannabis Control Commission in Massachusetts doesn’t allow cannabis businesses to advertise on most platforms unless data shows that they can reasonably expect at least 85% of the viewers to be 21 years old.

This policy encompasses radio, television, social media, billboards, mobile apps, podcasts and print media. So how exactly do the various social media platforms treat cannabis?

As it stands, you will most likely have your social media accounts deleted or banned if you use them to promote or advertise cannabis in America. Meta, which owns Facebook and Instagram, is one of the largest advertising platforms in the world, and it regularly cracks down on accounts that promote cannabis.

Twitter also considers cannabis to be federally illegal and will remove any content that promotes products and services related to cannabis. On the other hand, stakeholders say professional networking platform LinkedIn is the best social media platform to promote cannabis products. Anecdotal accounts show that LinkedIn is currently the most cannabis-friendly platform on the web.

According to Brooke Benavides, the marketing director at CMW Media, there has been growing conversation about cannabis on the networking platform. Unlike most other social media platforms, LinkedIn allows cannabis businesses to grow their platforms organically, Benavides says, providing industry professionals and businesses a platform to discuss matters relating to cannabis without fear of repercussion.

Reddit has also provided businesses in the cannabis sector an opportunity to increase awareness of their products. Via the Ask Me Anything (AMA) subreddit, which has more than seven hundred thousand members, players in the sector can have interactive sessions with the community.

Liz Gottbretch, director of Lantern, an organization that focuses on deliveries, says YouTube, Twitch, Pinterest and Alphabet Inc. are also home to several “cannabis adjacent communities” that cover topics such as food, gaming and how-to’s. These communities allow users to share content that is related to cannabis but doesn’t go against platform guidelines.

It might be valuable to evaluate the social media strategies of notable marijuana companies such as Cannabis Strategic Ventures Inc. (OTC: NUGS) in order to gain insights into how these types of companies manage to use any of those platforms without falling afoul of the stringent user guidelines.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Advanced Container Technologies Inc. (ACTX) Working to ‘Reshape Future of Farming’ Through Innovative GrowPods

Advanced Container Technologies (OTC: ACTX), the exclusive U.S. distributor of self-contained, automated, indoor “micro-farms” called GrowPods, along with related equipment and supplies., is building a reputation for leading the movement toward sustainable, clean-food farming. The company is committed to working toward reshaping the future of farming through the innovative GrowPods, which the company distributes exclusively. These GrowPods provide a way to grow food that is free from pathogens and pesticides, which is even better than organic, the company explains. According to the announcement, the current centralized food system inherently has risks, including widespread foodborne illness as well as spoilage caused by supply chain issues. In addition, the food distribution network contributes to carbon production and greenhouse gases because of the thousands of trucks used to haul food around the country. GrowPods, a form of shipping container farms, are powered by a unique automation software designed to make farming less labor intensive because the environment, nutrition and hydration levels are all controlled automatically. GrowPods not only create optimum growing conditions, they also simplify many aspects of farming, making it easier for inexperienced farmers, nonprofit organizations, restaurants, grocery stores and others to grow their own healthy, nutritious food. “It’s time to decentralize food production, and GrowPods have the power to do just that,” said Advanced Container Technologies CEO Doug Heldoorn in the press release. “GrowPods automate the growing process so that farmers can now even take a vacation.”

To view the full press release, visit https://cnw.fm/9H4K2

About Advanced Container Technologies Inc.

Advanced Container Technologies is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer(R), that store and grind pharmaceuticals, herbs, teas and other solids or liquids. For more information, visit the company’s website at www.AdvancedContainerTechnologies.com.

NOTE TO INVESTORS: The latest news and updates relating to ACTX are available in the company’s newsroom at https://cnw.fm/ACTX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Marijuana Firms Boost Online Sales by Leveraging UX Design

Due to restrictions placed on the cannabis market by federal prohibition, players in the nascent industry cannot market or sell their products through regular chains. Furthermore, patchwork cannabis regulations make it extremely tricky for cannabis businesses to expand to other states.

As a result, many cannabis businesses across the country are tapping into a resource that has essentially revolutionalized commerce: the internet. By building navigable and user-friendly websites, cannabis businesses can open up their market base without having to spend millions of dollars opening stores out of state.

Marijuana businesses are now investing in user-experience (UX) design to ensure their customers have a stress-free and enjoyable experience when shopping for products on their website. According to Socrates Rosenfeld, CEO of California-based Jane Technologies, shopping for cannabis “should be fun.”

Before the coronavirus pandemic struck, most cannabis consumers purchased their cannabis in physical brick-and-mortar shops. But as states across the country began to issue lockdown orders, cannabis businesses began offering online ordering, curbside pickup and home deliveries.

Home deliveries were especially crucial as a significant percentage of medical marijuana patients are immunocompromised and were much more likely to experience severe symptoms if they contracted COVID. By 2020, 22.7% of older adults used medical cannabis. According to the World Health Organization, age-related physiological changes coupled with possible underlying health conditions mean older people have a significant risk of becoming severely ill if they are infected with the virus.

Now that states are steadily lifting their lockdown orders, plenty of cannabis businesses plan on retaining their online presence. To lure customers away from brick-and-mortar stores, businesses that rely on online sales will have to make the experience even better than going into a store.

A good user-experience design will ensure that customers can navigate products as well as place and cancel orders easily. On average, a user will spend less than a minute on a webpage. If your UX design isn’t good enough to capture their attention in the first 10 seconds, they will most likely exit your website.

Cannabis clients and consumers tend to be more tech savvy compared to those in other industries, says Sam Harris, CEO of Springbing, a cannabis marketing and loyalty software company. As a result, they are more likely to know the difference between bad and good UX and will be critical of bad UX.

Andreas Neumann, the chief creative director of Florida-based Jushi Holdings, calls UX the “new branding.” He was hired because of his experience in design, and his main duty at Jushi is to ensure processes are as frictionless as possible for both customers and employees.

He notes that good UX doesn’t just make it easier for customers to navigate and make purchases, it also makes online communication for staff a lot easier and eliminates a lot of potential friction. Established companies such as Flora Growth Corp. (NASDAQ: FLGC) intuitively know that once staff work seamlessly, the bottom line of the company will benefit.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Analysis Shows Access to Recreational Cannabis Reduces Prescription Drugs Demand

Prescription drugs have got to be among the most influential human inventions of all time. Thanks to these medications, people have been able to recuperate from illnesses and injuries that would have otherwise taken their lives.

However, prescription medications aren’t without risk. Some of these medications have such serious side effects that they actually reduce the quality of life of patients while they are going through treatment. As such, there has been a push for alternative medicines for the past couple of years.

Cannabis has emerged as a possible alternative to pharmaceuticals. In fact, a recent analysis by researchers from Cornell University reveals that the demand for pricey prescription medications via state Medicaid programs tends to reduce with the passage of recreational cannabis laws.

Researchers found that as states have launched recreational cannabis markets, there has been a significant decline in the purchase of prescription meds meant to alleviate pain, anxiety, depression, insomnia, seizures and psychosis.

Titled “Recreational Cannabis Legalizations Associated with Reductions in Prescription Drug Utilizations Among Medicaid Enrollees,” the article reporting these findings was published in “Health Economics.” Shyam Raman, a Cornell Jeb. E Brooks School of Public Policy doctoral student, and Ashley Bradford, a doctoral student at Indiana University, conducted the research and penned the article.

According to Raman, the results of their study have major implications because they could save state Medicaid programs a significant amount of money. Additionally, they also provide an avenue for limiting reliance on pharmaceuticals and reducing the side effects synonymous with these medications, he says.

The two researchers obtained their findings by analyzing data collected from the Centers for Medicare and Medicaid Services in all states from 2011 to 2019. During this period, several states passed marijuana reforms and launched recreational cannabis markets, significantly increasing the public’s access to the substance.

Additionally, 40 states currently allow qualifying patients to use medical marijuana with a doctor’s prescription. Raman and Bradford specifically found a significant reduction in the demand for sleep and anxiety disorder drugs compared to nausea medications in these states.

Despite the uptick in Americans who are turning to cannabis as alternative medicine, Raman and Bradford note that the controversial plant is not completely harmless. This sentiment is in line with what many experts have said regarding marijuana’s exponentially growing popularity: the hype seems to have outpaced science by a wide margin.

Studies have found that excessive cannabis use has the potential to trigger anxiety and mental conditions such as schizophrenia. Furthermore, they say, patients who decide to use marijuana to treat their conditions without a doctor’s approval could create discontinuity in their primary care, which is why you shouldn’t be surprised when you see a variety of cannabis industry players, including American Cannabis Partners, recommending that people talk to their doctors before consuming marijuana products, especially those intended for therapeutic purposes.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Advancing DehydraTECH-Nicotine Research to Support Safer, More Effective Oral Alternative to Harmful Pulmonary Administration Practices

Lexaria expects to begin dosing this summer as part of a human nicotine study, NIC-H22-1, to compare DehydraTECH-nicotine pouch performance to that of existing leading brands such as ON! and Zyn
So far, the company’s animal studies have evidenced that the technology delivers outstanding results, including faster delivery, an increase in the quantity of peak nicotine delivered, higher brain levels of nicotine, and enhanced bioavailability
In its most recent study, Lexaria established that DehydraTECH-oral nicotine delivery peaked in bloodstream 10x to 20x faster than controls and peak levels achieved were up to 10x higher than controls
Lexaria’s research aims to support a safe alternative to the harmful, antiquated pulmonary nicotine administration practices, which claim 7.7 million lives annually

Since commencing in vivo studies evaluating its DehydraTECH technology for oral nicotine applications in 2018, global innovator Lexaria Bioscience (NASDAQ: LEXX) has primarily focused on animal studies that have proven the technology’s effectiveness in promoting faster absorption, higher peak absorption, and greater overall quantities of nicotine, on average, in the blood than concentration-matched control formulations. Building on the successes of these animal studies, Lexaria has now set its sights on a human nicotine study, NIC-H22-1, which is expected to begin dosing this summer (https://cnw.fm/4KP6s).

NIC-H22-1, a pharmacokinetic randomized, double-blinded, cross-over study involving 36 human participants, will compare Lexaria’s DehydraTECH-nicotine pouch performance to that of existing leading brands available to US consumers, namely ON! and Zyn. The study primarily aims to collect data on the maximum concentration of nicotine in the bloodstream (“Cmax), the time at which Cmax was reached (“Tmax”), and the area under the (“AUC”) – a parameter that indicates the total quantity of nicotine delivered over time – relative to controls. In addition, as part of its secondary objectives, the study NIC-H22-1 will include extensive subjective evaluations related to, among other things, the user experience and throat burn.

Ultimately, Lexaria hopes to evidence that DehydraTECH-processed purified nicotine improves oral tissue absorption and reduces negative experiences compared to brands currently sold to consumers.

Lexaria’s first animal study, whose results the company announced in April 2018, revealed that DehydraTECH delivered significant nicotine absorption performance improvements relative to controls. These included: 1,160% faster delivery of equivalent quantities of nicotine; 148% uptick in the quantity of peak nicotine delivered to the bloodstream; 560% higher brain levels of nicotine; enhanced bioavailability as evidenced by lower urine levels of nicotine; and lower quantities of key liver metabolites in the bloodstream, suggesting bypass of first-pass liver metabolism (https://cnw.fm/gKvXS).

Later in August 2018, Lexaria announced the results of an animal study showing the company had successfully delivered nicotine in an edible form into the blood plasma a few minutes after dosing. Notable highlights from the study included a 79% improvement in Cmax; a 94% enhancement in AUC, a 70% improvement, on average, in the speed of delivering the nicotine; and significantly greater absorption levels. According to Lexaria, this study corroborated and confirmed the validity of the April 2018 results (https://cnw.fm/3YNWB).

In 2021, the company announced its oral nicotine absorption study, NIC-A21-1, revealing that DehydraTECH-oral nicotine delivery peaked in bloodstream 10x to 20x faster than controls and peak levels achieved were up to 10x higher than controls (https://cnw.fm/ZnyOZ).

“Performance gains of this magnitude could be of great significance in enabling the oral pouch product category to offer improved nicotine satiety and effectiveness, with a goal of one day rendering pulmonary administration practices like smoking and vaping as obsolete,” Lexaria CEO Chris Bunka said of last year’s outstanding results.

Through its focus on oral nicotine products as well as its ever-growing portfolio of in vivo studies, Lexaria’s research aims to support a safer, more effective nicotine alternative to 1.1 billion smokers worldwide (as of 2019). With tobacco causing 1 in 5 deaths in males globally and roughly 7.7 million cumulative deaths annually (https://cnw.fm/H2Gyr), Lexaria’s DehydraTECH technology, which has so far delivered outstanding results in animals, could help the millions of users move away from the harmful smoking habit. And the upcoming human study is expected to inch the company closer to realizing this goal. In fact, Lexaria is optimistic this larger human study will produce positive findings pursuant to those evidenced by the 2021 study.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive instant SMS alerts, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Schumer Postpones Tabling Cannabis Legalization Bill as Consultations Continue

Senate Majority Leader Chuck Schumer has made it clear that he is a strong supporter of comprehensive marijuana reform at the federal level. For the past couple of months, he has been working with Senator Cory Booker and Senate Finance Committee Chair Ron Wyden on a bill that would federally legalize cannabis and regulate sales.

Dubbed the Cannabis Administration & Opportunity Act (CAOA), Schumer’s bill was first unveiled in 2021 to mixed reviews. The draft bill intended to deschedule cannabis at the federal level, expunge prior nonviolent cannabis convictions from people’s records, allow states to continue running their own cannabis markets, and even allow people with prior cannabis convictions to petition for resentencing.

It would also use some of the funds raised from marijuana sales for programs that support communities that were disproportionately affected by the war on drugs.

Schumer has now revealed that he will not introduce his Cannabis Administration & Opportunity Act this month due to a timeline extension. The additional time will be spent working on various provisions with the help of more than 10 Senate committees and input from several federal agencies. The senate majority leader had said on numerous occasions that he would formally file the federal legalization bill by the end of April. The legislation’s official introduction has now been pushed to sometime before the August recess.

Two weeks ago, Schumer revealed that he and his colleagues had reached out to GOP senators to see what they would like to see included in his bill before he formally unveiled it. At the time, he said that they hoped to file the bill towards the end of April.

Although stakeholders in the nascent cannabis sector would love to get a federal legalization bill as soon as possible, taking their time will allow Schumer and his colleagues to drum up more support for the CAOA. At the moment, Democrats hold a slim majority in the Senate and are unlikely to pass the federal cannabis legalization bill without GOP support.

For instance, the Secure and Fair Enforcement (SAFE) Banking Act has advanced past the House several times but keeps stalling in the Senate.

In a press release, Schumer called his cannabis bill a “critical legislation” that will finally lift federal cannabis prohibition and attempt to alleviate the damage caused by the over-criminalization of cannabis. He said that his bill would not only strike cannabis from the country’s list of controlled substances, but it would also promote restorative justice, help to repair the country’s criminal justice system and protect public health.

If this delay results in better chances of the measure being passed, the wait will be worthwhile to the entire cannabis industry, including major sector players such as Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF).

NOTE TO INVESTORS: The latest news and updates relating to Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) are available in the company’s newsroom at https://cnw.fm/RWBYF

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Congressional Bill Wants Parity Between Cannabis, Alcohol-Linked Punishments in the Military

Ever since states started legalizing cannabis, the sector has existed in a precarious position, allowed by state law but prohibited by federal law. More than once, consumers have found themselves penalized for doing activities that are allowed by state law, such as consuming cannabis, by organizations that abide by federal law.

For starters, military service members who are found in possession of up to 30 grams of marijuana are eligible for a maximum punishment of dishonorable discharge, two-year confinement, and forfeiture of all their pay and allowances.

Given that some studies have found that cannabis can help alleviate the PTSD many active and retired service members suffer from, these penalties are quite harsh. Possession of more than 30 grams of cannabis can result in up to five years of confinement. Consequently, Rep. Anthony Brown has introduced a new bill to Congress that would do away with most of these harsh penalties.

The Restoring Equity for Offenses Related to Marijuana (REFORM) Act would make it so that the penalties for using marijuana wrongfully do not exceed the penalties for being found while on duty. Furthermore, the text of the legislation states that the punishment for wrongful cannabis possession shouldn’t exceed the penalties for incapacitation for work due being drunk or having used a drug.

Compared to the penalties military service members are subject to if they are found in wrongful possession of cannabis, being incapacitated for duty due to alcohol consumption can lead one to forfeit two-thirds of their salary for three months or confinement for three months. Service members who are drunk while on duty face discharge due to bad conduct, total forfeiture of their pay and allowances, and up to nine months of confinement.

Brown’s bill seeks to remove the disparity between the punishments for alcohol and cannabis possession and use. Speaking to Marijuana Moment, he noted that cannabis prosecutions tend to disproportionately affect service members of color. Black service members are even more likely to be investigated and prosecuted for offenses connected to drugs, he notes. Calling the current zero-tolerance marijuana policy outdated, he says that it is “disconnected from the present reality,” especially when considering the fact that many service members enlist from states with legal cannabis markets.

On top of equalizing the penalties for cannabis and alcohol use, the REFORM Act would also require that military branches send annual reports about drug evaluation and testing programs to congressional defense committees.

As the hallmarks of cannabis prohibition initiated decades ago are rolled back, people are discovering plenty of cutting-edge cannabis cultivation technologies, such as the Grow Pods manufactured by Advanced Container Technologies Inc. (OTC: ACTX) leading to superior marijuana products than those sourced from illicit vendors on the street.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Well Positioned for Opportunity

Flora Growth Corp. (NASDAQ: FLGC) has expanded its portfolio, which spans a range of verticals and diverse revenue streams, with growth largely driven through mergers and acquisitions (“M&As”). With M&As defining its 2021 calendar year, Flora Growth capitalized on global trends, which saw over 63,000 worldwide M&A transactions completed across all industries and sectors as companies sought new avenues for growth amid the pandemic, rising inflation and disrupted supply chains. With two recent acquisitions, Flora Growth “was able to add an estimated $35 million in revenues and $7 million EBITDA. For comparison, back in 2020, the company’s acquisitions generated $28 million in revenue and $7 million in EBITDA,” a recent article reads. “Flora Growth has also raised about $35 million in capital and added several key executives, positioning itself for upcoming growth. It is projected that the overall global momentum for M&A activity will continue through the 2022 calendar year, and Flora Growth will be at the forefront of it all.”

To view the full article, visit https://cnw.fm/vT8lO

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands delivering the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. Visit www.FloraGrowth.ca or follow @floragrowthcorp on social media for more information.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.